Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Gap Up on Earnings Beat

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)’s stock price gapped up prior to trading on Tuesday following a better than expected earnings announcement. The stock had previously closed at $214.44, but opened at $225.37. Jazz Pharmaceuticals shares last traded at $232.0350, with a volume of 647,883 shares trading hands.

The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.05) by $0.17. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company earned $8.13 earnings per share.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Raised 2026 guidance: Jazz now expects approximately $4.8 billion-$4.9 billion in full-year revenue, above the roughly $4.7 billion analyst consensus. The company cited sustained commercial execution and expects the Ziihera launch to support growth. Jazz Pharmaceuticals 2026 revenue guidance
• Positive Sentiment: Q3 beat expectations: Jazz reported quarterly revenue of $1.24 billion, up 10.4% year over year and ahead of the $1.21 billion consensus. Its adjusted loss of $3.88 per share was narrower than the expected $4.05 loss. Xywav revenue grew 12%, with 425 net patient additions during the quarter. Jazz Pharmaceuticals third-quarter 2026 results
• Positive Sentiment: Analyst optimism: Royal Bank of Canada raised its price target to $305 and retained an “outperform” rating, while Barclays increased its target to $275 and maintained an “overweight” rating. The revisions reinforce expectations for additional upside. Royal Bank of Canada Jazz Pharmaceuticals rating
• Neutral Sentiment: Jazz launched Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma and says the product could eventually reach $3 billion-$5 billion in peak sales. The company also completed its Actio acquisition, adding the ABS-1230 epilepsy candidate.
• Neutral Sentiment: Jazz will present Phase 3 ACTION trial and other neuro-oncology data at the Society for Neuro-Oncology meeting later this month, creating a potential near-term catalyst but with clinical-outcome uncertainty. Jazz Pharmaceuticals neuro-oncology research
• Negative Sentiment: The quarterly loss compares with $8.13 in earnings per share a year earlier, while some commentary highlighted slowing growth and charges related to the Actio acquisition. These factors could limit enthusiasm despite the revenue beat.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Morgan Stanley upped their price objective on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an “overweight” rating in a research report on Tuesday. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $276.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Barclays boosted their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday. Stifel Nicolaus set a $275.00 price objective on Jazz Pharmaceuticals in a report on Tuesday, August 4th. Finally, Wall Street Zen lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $292.95.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Renée Galá sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total value of $472,800.00. Following the completion of the sale, the chief executive officer owned 141,394 shares of the company’s stock, valued at approximately $33,425,541.60. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the sale, the director owned 345,875 shares of the company’s stock, valued at approximately $79,665,388.75. This represents a 1.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 94,121 shares of company stock worth $23,337,922. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in Jazz Pharmaceuticals by 44.5% in the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after acquiring an additional 517,514 shares during the period. Bank of America Corp DE grew its stake in shares of Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. Systematic Financial Management LP increased its position in shares of Jazz Pharmaceuticals by 2.6% during the 1st quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock valued at $76,965,000 after purchasing an additional 10,237 shares during the last quarter. Quantinno Capital Management LP increased its position in shares of Jazz Pharmaceuticals by 9.7% during the 1st quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock valued at $36,163,000 after purchasing an additional 16,928 shares during the last quarter. Finally, Tri Locum Partners LP purchased a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at about $29,995,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 8.2%

The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The stock has a market cap of $15.06 billion, a P/E ratio of 16.02, a PEG ratio of 0.41 and a beta of 0.38. The company’s 50 day moving average price is $231.16 and its two-hundred day moving average price is $216.50.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.